The ability of the atypical antipsychotic drug candidate olanzapine to antagonize dopamine, serotonin, alpha-adrenergic and muscarinic receptors in vivo was assessed by various neurochemical ...

This is in contrast to antipyschotics such as olanzapine, which bind strongly to a range of neurotransmitter receptors. Although the effects of LY2140023 in the long term, its optimal dosage and ...

Am J Health Syst Pharm. 2008;65(12):1180-1183. Ultimately, more formalized, high-quality, and clinically applicable studies are necessary to determine the safety of the parenteral combination of ...

This suggests that olanzapine could be a valuable addition ... Additionally, a head-to-head study comparing two neurokinin-1 receptor antagonists, fosnetupitant and fosaprepitant, found that ...

Olanzapine is an atypical antipsychotic and ... to the schizophrenia treatment landscape by targeting cholinergic receptors ...